Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase Ia/b Dose Escalation Followed by Dose Expansion Safety and Tolerability Trial of CAP-100, a Humanized C-C-chemokine Receptor 7 Antibody, Administered as Monotherapy in Subjects With r/r Chronic Lymphocytic Leukemia

NCT04704323 is registered in ClinicalTrials.gov with Catapult Therapeutics as lead sponsor.

NCT NCT04704323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04704323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase Ia/b Dose Escalation Followed by Dose Expansion Safety and Tolerability Trial of CAP-100, a Humanized C-C-chemokine Receptor 7 Antibody, Administered as Monotherapy in Subjects With r/r Chronic Lymphocytic Leukemia
Lead sponsor
Catapult Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
September 10, 2021
Completion date
April 30, 2027
Enrollment
18 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lymphocytic leukemia, chronic, sll